<SEC-DOCUMENT>0001213900-25-124292.txt : 20251222
<SEC-HEADER>0001213900-25-124292.hdr.sgml : 20251222
<ACCEPTANCE-DATETIME>20251222114955
ACCESSION NUMBER:		0001213900-25-124292
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251222
FILED AS OF DATE:		20251222
DATE AS OF CHANGE:		20251222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41084
		FILM NUMBER:		251590862

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0270556-6k_neuro.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer Pursuant to Rule&nbsp;13a-16
or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of December 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-41084</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Therapeutics Ltd.<BR>
</B>(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>11 HaMenofim Street, Building B<BR>
Herzliya 4672562 Israel<BR>
+972-9- 7996183<BR>
</B>(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;20-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Explanatory Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Attached is the
Company&rsquo;s press release regarding confirming favorable safety and tolerability of PrimeC in an Alzheimer&rsquo;s Phase 2 study,
furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This Report on Form 6-K
<FONT STYLE="background-color: white">(other than the fourth paragraph in Exhibit 99.1)</FONT> is hereby incorporated by reference into
the registrant&rsquo;s Registration Statements on&nbsp;<FONT STYLE="background-color: white">Form S-8&nbsp;(File&nbsp;No.&nbsp;</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390022005072/ea154846-s8_neurosense.htm"><FONT STYLE="background-color: white">333-262480&nbsp;</FONT></A>and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390025077513/ea0252622-s8_neurosense.htm">333-289658</A><FONT STYLE="background-color: white">)
and&nbsp;Form&nbsp;F-3&nbsp;(File No.&nbsp;</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390023003838/ea171892-f3_neurosense.htm"><FONT STYLE="background-color: white">333-269306</FONT></A><FONT STYLE="background-color: white">,&nbsp;</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390024030451/ea0203321-posam_neurosense.htm"><FONT STYLE="background-color: white">333-260338</FONT></A><FONT STYLE="background-color: white">,&nbsp;</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390024106506/ea0223814-f3_neuro.htm"><FONT STYLE="background-color: white">333-283656</FONT></A>,
<A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390024112695/ea0226024-f3_neurosense.htm"><FONT STYLE="background-color: white">333-284051</FONT></A>
and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390025103109/ea0262630-f3_neurosense.htm">333-291122</A>) to be
a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><B>Exhibit&nbsp;No.</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left; width: 90%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD><U><A HREF="ea027055601ex99-1_neuro.htm">Press Release dated December 22, 2025</A></U></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>NeuroSense Therapeutics Ltd.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: December 22, 2025</TD>
    <TD>By:&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ Alon Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Alon Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea027055601ex99-1_neuro.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 22, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Confirms Favorable Safety and Tolerability
of PrimeC in an Alzheimer&rsquo;s Phase 2 Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical and Biomarker Outcomes Expected to
Be Reported in Q1 2026</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CAMBRIDGE, Mass.,&nbsp;Dec. 22, 2025&nbsp;/PRNewswire/
--&nbsp;NeuroSense Therapeutics Ltd.&nbsp;(NASDAQ: NRSN) (&ldquo;NeuroSense&rdquo;), a late-clinical stage biotechnology company developing
novel treatments for&nbsp;severe neurodegenerative diseases, today reported completion of the safety analysis from its proof-of-concept
Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC combination in Alzheimer&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The safety analysis indicated a favorable tolerability
profile for PrimeC. No serious adverse events were reported, and no new or unexpected safety signals were identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an exploratory proof-of-concept study, clinical
outcome measures are descriptive by design. NeuroSense will analyze clinical observations alongside biomarker data to enable a more comprehensive
interpretation of the clinical observations, with results expected in the first quarter of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About </B></FONT><B>Alzheimer&rsquo;s
<FONT STYLE="background-color: white">Disease</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><FONT STYLE="background-color: white">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><FONT STYLE="background-color: white"></FONT></B>Alzheimer&rsquo;s <FONT STYLE="background-color: white">disease (AD) is a progressive neurodegenerative disorder and the leading
cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and
behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet
need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease
mechanisms simultaneously, </FONT>such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PrimeC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PrimeC, NeuroSense&rsquo;s lead drug candidate, is a novel extended-release
oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed
to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation
and impaired ribonucleic acid (&ldquo;RNA&rdquo;) regulation to potentially inhibit the progression of ALS and AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About&nbsp;NeuroSense</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company
focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes
that these diseases, which include amyotrophic lateral sclerosis&nbsp;(ALS), Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease, among others,
represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients
to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers,
NeuroSense&rsquo;s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For additional information, we invite you to visit our&nbsp;website&nbsp;and
follow us on&nbsp;LinkedIn,&nbsp;YouTube&nbsp;and&nbsp;X. Information that may be important to investors may be routinely posted on our
website and these social media channels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &ldquo;forward-looking statements&rdquo;
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; &ldquo;would,&rdquo; or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense Therapeutics&rsquo; current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to
predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking
statements, including statements regarding the timing of the reporting of additional data from the study of PrimeC in Alzheimer&rsquo;s disease,
are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual
results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include
the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data, including from the
study of PrimeC in Alzheimer&rsquo;s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and
other risks and uncertainties set forth in NeuroSense&rsquo;s filings with the Securities and Exchange Commission (SEC). You should not rely
on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is
contained under the heading &ldquo;Risk Factors&rdquo; in the Annual Report on Form 20-F filed with the Securities and Exchange Commission
on April 7, 2025 and NeuroSense&rsquo;s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made
as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !6 4<# 2(  A$! Q$!_\0
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M746H:?>6TI81S6M]9F:TG1MIPT<S*!R2*U_-/("^N#DE3@D$;@I 88Y!P,D
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MC,JS#!9EA+I+%8'%4,7AY-](5J%6K3FU]I1E>+TDD3T5%YA_N\YQUQQ_>_\
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M<8?=Y4"!I 1,P5%\Q0@W?E=_P5._96\)_ +QOX-\9^&/$GB[7KCXO:MX^O\
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MP[+!!X3TDK(K212V&AQ7B>9M:_NHEAEKZF_9TT#P5X8^!OPIT3X=K9IX+M/
MGA0:!-9-%Y%[8S:587,6I2SP*C7<VK-<2:D92K_:KFZGGN"DTQ0>Y*K%0 Q!
M*\$KAR<Y.X #!ZCWZ]Z_@SQK^DEXD>(&>YOEE+.LTX=X9PF/S#!83(\LQ%3
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M2I]'EMI;V_GU;4K2PLEG%[:1JU_&Z?:98)(G^@_C)\ _@_\ M ^'9/"OQ;\
M^'_&&FRV\T-E-J-H%U;33=(NZ71-;A%OK6A7;QQJ'GTN_LY 2ZS&9 0WQA^W
MY_P3^\0?M8>(/ ?Q%\"?%)OASX]^'6G7EGI/VS2[V\TR\DEUBRU[3K[^U-(O
M+/5]%U'1]2L4GL;V--5@BWD'3B3(TWA.C_"G_@LUI-@/"D'QX^!.JV*0+8P>
M,-6LWN=:AMT1E2=YU^&L+WDR ^8DVHV%[/YA/S\!Z_H7 <.<(X_(.#.(N#_$
MC(N#.,<%@*\>*\+GN*XBRJO1S3"9C*KALURK'8/!XJE)5L#*G26#PM6BH5:,
MI>SFW*$OTK$\0\79%G7%_"'&7AGQ#QKP/4KX'"\$5<BPF09KAZ^3PRNCAJ^7
MYOA<97I8B$?K=)5(8FM"K4BVE*K"+YS\8?'/PNU/]E7]OO3?AQ\+M<O]9U'P
M-\9_AK-X)U SI-JUU;^+K_P]?V&CZE%I^R.34DLO$=SX9U>>.RLK76X7N9KR
M*:2<6-A[G_P5D\/ZCX*_;E'C#Q'HO]LZ!XE\+?#+Q/8Z7<1I);>(=*\-R#2=
M=\/Q(Y8RK,_AZYL[^W@"M&NL64DWEP7J7)_7_P#9+_X)EV?PF^*-Q^T-\?/B
M)-\;OCE=7U[K5IJ=Q:RQ:!X>U_581#?ZU:F^FN-0UW6XK;=IND:EJ!LK+1M*
M(M]-T.UO8H=0C^G/VQOV,?AM^V#X"M_#'BV>YT#Q-H5Q<WW@OQQI=M'-J?AO
M4+F$1SP2PN4_M/P]?O#;-JF@SW$5M>&UM)HYK2]L-/O+3^B:_P!)?A/ >*GA
M]F.*QU;B?+,AX QW ?&G&^'P<L/7S/%Y[3PT<=G>5494:6-]GEE;#QG2K8B$
M:V*;Q%:E2I>TY9_SI@_HM<;8WPD\1L%A<#1X?SCB/C[ <<\&\"8_%QQ&'RS!
M9#4Q$\)DN93A6E@_:9G1K.$J="I&GAE[.G.I-TXR7E?PP_8T_P""?/Q8\">%
M?B%X$^!WPB\0^&_%6CVVJZ1JUCI*2+-:SL':WN4CG<VM]:S1S6>I:?,(KG3-
M4MKNSNH(KJ.>!/1_ /[/7[$_P5^,/AJQ^'W@#X4>!/C5<:!KVK>%+'25TZQ\
M8S>'3&FF:]J6G6AN);^XL=EVMG=R"%QM:=S&(;2[D@_'SPO_ ,$PO^"AGP8U
M._T7X,?M(Z!X;\*:EJ GFO=%\??$/PI:7)W!&U*\\)1>&M<TNUU&XB&;MK:Y
MU"63]VMM>VRQQB/].OV._P!@Z']G76=>^+/Q.\>:G\;/VA_%EA]AU3XAZ^^H
MWJ:-I5TT+7&C>&3K5]JVK);W$B1+JFK7UV;[4+:UMK5;>SL(6M)_Q/CS#Y#D
M^"SNKEGT@,9Q?E&/CB:609%@*O$D<?CH8VO*5*CQ"LPJ4<HPN#P]*I-8WEEB
M:^)G3C]6PT95IRI_N/AUBN(,YQO#^'S/Z.&5\(YUE%7"/B3B+%T<B^J9>L!A
M)49UN'70@\SQF,Q52G!X5P<*%+VK5?$3A!7_ "E_X+L3,_Q;^"T: '[/\,_&
M%PJ-&SNLTFO6RH7A023M%(%P28V150,JD-A?Z./AMG_A7?@8!F*GPKX;V[@7
M+1C2+$!F8('W.I$IW)&<G+*@RU?A=^TQ_P $UOVYOVJ/&Z>+_BA\8O@9J/\
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MN4JV*:ISQ+2C[.G0A"F,<!B&"_,?E'<<@D\;7 !P%8LN,$#+$XJ!C'& Q&T
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M^\<D99NGH!R<X]\_AC%>)?$S]I7X!_!O7=#\+?$[XO?#[P5XI\3WNBZ?X?\
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MVO# 'D<OZIXE_P""<.I:=\8_B)\5_P!GC]JGXR_LRV?QHUE?$7Q?\#^ =/\
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MK.5Q-'#<J\4I3;.) [Y_/+X#_L'>.?@E\>_''Q]E_:N\=^.-;^+=]I%[\8=
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
